About Zinc finger CCHC domain-containing protein 18
Zinc finger CCHC domain-containing protein 18 (ZCCHC18) is a protein
from Homo sapiens identified by UniProt accession
P0CG32, 403 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Zinc finger CCHC domain-containing protein 18 |
|---|
| UniProt accession | P0CG32 |
|---|
| Gene | ZCCHC18 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 403 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (8)
Diseases linked to this target (Open Targets).
- chronic lymphocytic leukemia · score 0.02
- Ataxia-telangiectasia · score 0.01
- acute myeloid leukemia · score 0.01
- acute lymphoblastic leukemia · score 0.01
- pituitary cancer · score 0.01
- diffuse large B-cell lymphoma · score 0.00
- follicular lymphoma · score 0.00
- diabetes mellitus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0CG32-F1 | alphafold | PREDICTED | 68.96 | — |
Amino-acid sequence (403 residues)
MASITACVGN SRQQNAPLPP WAHSMLRSLG RSLCPLVVKM AERNMKLFSG RVVPAQGKET FENWLIQVNE VLPDWSMSEE EKLKRLMKTL RGPAREVMRL LQAANPNLSV ADFLRAMKLV FGESESSVTA HGKFFNTLQA QGEKASLYVI RLEVQLQNAI QAGILAEKDA NQTRLQQLLL GAELNRDLRF RLKHLLRMYA NKQERLPNFL ELIKMIREEE DWDDAFIKRK RPKRSEPIME RAASPVAFQG AQPIAISSAD CNCNVIEIDD TLDDSDEDVI LVVSLYPSLT PTGAPPFRGR ARPLDQVLVI DSPNNSGAQS LSTSGGSGYK NDGPGNIRRA RKRKYTTRCS YCGEEGHSKE TCDNESNKAQ VFENLIITLQ ELTHTEERSK EVPGEHSDAS EPQ
Explore Zinc finger CCHC domain-containing protein 18 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets